Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in Pediatric Cancer Models in Poster Presentation at EORTC-NCI-AACR 2022
October 12 2022 - 4:04AM
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to
transforming the lives of those affected by cancer, today announced
that it will present preclinical data in a poster at the
EORTC-NCI-AACR Symposium on Molecular Targets and Cancer
Therapeutics in Barcelona, Spain. The meeting will be held from
Oct. 26-28, 2022.
The poster will include preclinical data
demonstrating that Kronos Bio’s internally discovered oral CDK9
inhibitor, KB-0742 induced regressions in a preclinical model of
MYCN-amplified neuroblastoma tumors and inhibited growth in
patient-derived xenograft (PDX) models of transcriptionally
addicted Ewing sarcoma (EW) and alveolar rhabdomyosarcoma
(ARMS).
This is the first preclinical analysis to
support the investigational compound’s potential in pediatric
tumors. KB-0742 is being developed for the treatment of
MYC-amplified and transcriptionally addicted solid tumors and is
currently being assessed as part of an ongoing Phase 1/2 study.
Kronos Bio remains on track to provide an update on the study,
including the Recommended Phase 2 Dose (RP2D) in the fourth
quarter.
The abstract is now available on the conference
website. Details of the poster presentation are as follows:
Poster Title: Regulation of oncogenic
transcription and tumor growth in pediatric cancers by the CDK9
inhibitor KB-0742 Abstract Number:
PB088Date and Time: Oct. 27, 10 a.m. Central
European Time
About KB-0742KB-0742 is a
highly selective, orally bioavailable inhibitor of cyclin dependent
kinase 9 (CDK9) in development for the treatment of MYC-amplified
solid tumors. CDK9 is a global regulator of transcription and plays
an essential role in both the expression and function of MYC, a
well-characterized transcription factor and a long-recognized
driver of cancer that is amplified in approximately 30% of solid
tumors, including those affecting the lungs, ovaries and breast.
KB-0742 was generated and optimized from a compound that was
identified using the company’s proprietary small molecule
microarray (SMM) screening platform.
About Kronos Bio, Inc.Kronos
Bio is a biopharmaceutical company that is advancing three
investigational compounds in clinical trials for patients with
cancer. The company’s lead compound, the SYK inhibitor
entospletinib, is being evaluated in the registrational Phase 3
AGILITY trial as a treatment for patients with newly diagnosed
NPM1-mutated acute myeloid leukemia (AML). The company is also
developing the CDK9 inhibitor, KB-0742, as a treatment for
MYC-amplified solid tumors and lanraplenib, a next-generation SYK
inhibitor being assessed in patients with FLT3-mutated AML. The
company’s scientific focus is on developing medicines that target
the dysregulated transcription that is the hallmark of cancer and
other serious diseases.
Kronos Bio is based in San Mateo, Calif., and
has a research facility in Cambridge, Mass. For more information,
visit www.kronosbio.com or follow the company on LinkedIn.
Forward-Looking
StatementsStatements in this press release that are not
statements of historical fact are forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The press release, in some cases,
uses terms such as “on track to,” “plan,” “potential,” “will” or
other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. Forward-looking
statements include statements regarding Kronos Bio’s intentions,
beliefs, projections, outlook, analyses or current expectations
concerning, among other things, Kronos Bio’s plan to provide an
update and recommended Phase 2 dose for the KB-0742 study,
KB-0742’s potential in pediatric tumors and other statements that
are not historical fact. Actual results and the timing of events
could differ materially from those anticipated in such
forward-looking statements as a result of various risks and
uncertainties, including, without limitation: whether Kronos Bio
will be able to progress the Phase 1/2 clinical trial of KB-0742 on
the timeline anticipated, including due to risks associated with
the COVID-19 pandemic and risks inherent in the clinical
development of novel therapeutics; risks related to Kronos Bio’s
lack of experience as a company in conducting clinical trials; the
risk that results of preclinical studies and early clinical trials
are not necessarily predictive of future results; and risks
associated with the sufficiency of Kronos Bio’s cash resources and
need for additional capital. These and other risks are described in
greater detail in Kronos Bio’s filings with the Securities and
Exchange Commission (SEC), including under the heading “Risk
Factors” in its Quarterly Report on Form 10-Q for the quarter ended
June 30, 2022, filed with the SEC on August 4, 2022. Any
forward-looking statements that are made in this press release
speak only as of the date of this press release and are based on
management’s assumptions and estimates as of such date. Except as
required by law, Kronos Bio assumes no obligation to update the
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
Company Contact:Marni KottleSenior Vice
President, Corporate Communications & Investor
Relations415-218-7111mkottle@kronosbio.com
Investors:Claudia StyslingerArgot
Partners212-600-1902kronosbio@argotpartners.com
Media:Sheryl SeapyReal
Chemistry949-903-4750sseapy@realchemistry.com
Kronos Bio (NASDAQ:KRON)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kronos Bio (NASDAQ:KRON)
Historical Stock Chart
From Jul 2023 to Jul 2024